<p>TransMedics Group（納斯達克代碼：TMDX - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 從 “持有” 評級上調至 “買入” 評級。</p>
<p>獲取 <strong>TransMedics Group</strong> 的提醒：</p>
<ul>
<li>中型股奇蹟：三隻在五月超越銷售預期的股票</li>
</ul>
<p>TMDX 還受到其他幾份報告的關注。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 TransMedics Group 股票的 “持有（c）” 評級。Canaccord Genuity Group 在週二的報告中重申了 “買入” 評級，並設定了 142.00 美元的目標價。Needham &amp; Company LLC 在 8 月 25 日的報告中重申了對 TransMedics Group 股票的 “持有” 評級。Evercore ISI 在 9 月 16 日的研究報告中開始覆蓋 TransMedics Group 股票。他們給予該股票 “跑贏大盤” 的評級，並設定了 155.00 美元的價格目標。最後，Stifel Nicolaus 在 9 月 4 日的研究報告中開始覆蓋 TransMedics Group 股票。他們設定了 “持有” 評級和 115.00 美元的目標價。七位分析師對該股票給予了買入評級，六位分析師給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 127.18 美元。</p>
<p><strong>閲讀我們關於 TransMedics Group 的最新報告</strong></p>
<h2>TransMedics Group 股票上漲 1.7%</h2>
<ul>
<li>三隻醫療科技股票在 2025 年表現優異</li>
</ul>
<p>納斯達克：TMDX 週五開盤價為 117.63 美元。TransMedics Group 的 52 周低點為 55.00 美元，52 周高點為 145.50 美元。該股票的市值為 40.1 億美元，市盈率為 60.95，貝塔值為 2.08。公司的債務與股本比率為 1.61，速動比率為 9.17，流動比率為 9.86。公司的 50 日簡單移動平均線為 116.52 美元，200 日簡單移動平均線為 113.37 美元。</p>
<p>TransMedics Group（納斯達克代碼：TMDX - 獲取免費報告）最後一次發佈季度財報是在 7 月 30 日。該公司報告本季度每股收益為 0.92 美元，超出分析師共識預期的 0.48 美元，超出幅度為 0.44 美元。TransMedics Group 的淨利潤率為 13.49%，股本回報率為 28.02%。該公司本季度的收入為 1.5737 億美元，而分析師預期為 1.4664 億美元。去年同期，該公司每股收益為 0.35 美元。與去年同期相比，該公司的收入增長了 37.7%。TransMedics Group 已設定其 2025 財年的每股收益指導。平均而言，股票分析師預計 TransMedics Group 本財年將發佈 1 美元的每股收益。</p>
<h2>TransMedics Group 的機構交易</h2>
<ul>
<li>三隻高增長股票，交易者熱愛，投資者應關注</li>
</ul>
<p>幾家機構投資者和對沖基金最近買入和賣出了該股票的股份。瑞銀資產管理美國有限公司的一個獨立業務部門在第一季度將其在 TransMedics Group 的持股增加了 244.7%。瑞銀資產管理美國有限公司的一個獨立業務部門現在擁有 3,113,082 股該公司的股票，價值 209,448,000 美元，在此期間又購買了 2,209,996 股。Geode Capital Management LLC 在第二季度將其在 TransMedics Group 的持股增加了 1.4%。Geode Capital Management LLC 現在擁有 804,650 股該公司的股票，價值 107,845,000 美元，在此期間又購買了 11,241 股。Driehaus Capital Management LLC 在第一季度將其在 TransMedics Group 的持股增加了 2.4%。Driehaus Capital Management LLC 現在擁有 778,754 股該公司的股票，價值 52,395,000 美元，在此期間又購買了 17,913 股。Marshall Wace LLP 在第二季度將其在 TransMedics Group 的持股增加了 258.7%。Marshall Wace LLP 現在擁有 546,787 股該公司的股票，價值 73,275,000 美元，在此期間又購買了 394,340 股。最後，高盛集團在第一季度將其在 TransMedics Group 的持股增加了 20.6%。高盛集團現在擁有 507,510 股該公司的股票，價值 34,145,000 美元，在此期間又購買了 86,721 股。99.67% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>TransMedics Group 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>TransMedics Group, Inc 是一家商業階段的醫療技術公司，致力於為美國及國際上的終末期器官衰竭患者轉變器官移植治療。該公司提供器官護理系統（OCS），這是一種便攜式器官灌注、優化和監測系統，利用其專有和定製技術在人體外複製接收器官的近生理條件。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 TransMedics Group</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>便士股票是否適合你的投資組合？</li>
<li>博通與 OpenAI 達成協議：為什麼這對 AVGO 股票是一個巨大的勝利</li>
<li>紐約證券交易所和納斯達克的區別，為什麼這對投資者很重要</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 TransMedics Group 嗎？</h2>
<p>在你考慮 TransMedics Group 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 TransMedics Group 並不在名單上。</p>
<p>雖然 TransMedics Group 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TMDX

<p>華爾街禪將 TransMedics Group（NASDAQ:TMDX）的評級從 “持有” 上調至 “買入”。該股票獲得了分析師的混合評級，其中包括七個買入評級和六個持有評級。目前，TMDX 的交易價格為 117.63 美元，市值為 40.1 億美元，市盈率為 60.95。公司在上個季度報告的每股收益為 0.92 美元，超出預期，收入同比增長 37.7%。機構投資者持有 99.67% 的股份，顯示出對公司的強烈興趣</p>

<p>TransMedics Group (NASDAQ:TMDX - Get Free Report) was upgraded by Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>TransMedics Group（納斯達克代碼：TMDX - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 從 “持有” 評級上調至 “買入” 評級。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股奇蹟：三隻在五月超越銷售預期的股票</li>
</ul>
</div><p>TMDX has been the subject of several other reports. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a &#34;buy&#34; rating and set a $142.00 target price on shares of TransMedics Group in a report on Tuesday. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of TransMedics Group in a report on Monday, August 25th. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an &#34;outperform&#34; rating and a $155.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a &#34;hold&#34; rating and a $115.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $127.18.</p>
<div class="lb-trans"><p>TMDX 還受到其他幾份報告的關注。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 TransMedics Group 股票的 “持有（c）” 評級。Canaccord Genuity Group 在週二的報告中重申了 “買入” 評級，並設定了 142.00 美元的目標價。Needham &amp; Company LLC 在 8 月 25 日的報告中重申了對 TransMedics Group 股票的 “持有” 評級。Evercore ISI 在 9 月 16 日的研究報告中開始覆蓋 TransMedics Group 股票。他們給予該股票 “跑贏大盤” 的評級，並設定了 155.00 美元的價格目標。最後，Stifel Nicolaus 在 9 月 4 日的研究報告中開始覆蓋 TransMedics Group 股票。他們設定了 “持有” 評級和 115.00 美元的目標價。七位分析師對該股票給予了買入評級，六位分析師給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 127.18 美元。</p>
</div><p><strong>Read Our Latest Report on TransMedics Group</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 TransMedics Group 的最新報告</strong></p>
</div><h2>TransMedics Group Stock Up 1.7%</h2>
<div class="lb-trans"><h2>TransMedics Group 股票上漲 1.7%</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻醫療科技股票在 2025 年表現優異</li>
</ul>
</div><p>NASDAQ:TMDX opened at $117.63 on Friday. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $145.50. The stock has a market capitalization of $4.01 billion, a P/E ratio of 60.95 and a beta of 2.08. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The company's 50-day simple moving average is $116.52 and its 200-day simple moving average is $113.37.</p>
<div class="lb-trans"><p>納斯達克：TMDX 週五開盤價為 117.63 美元。TransMedics Group 的 52 周低點為 55.00 美元，52 周高點為 145.50 美元。該股票的市值為 40.1 億美元，市盈率為 60.95，貝塔值為 2.08。公司的債務與股本比率為 1.61，速動比率為 9.17，流動比率為 9.86。公司的 50 日簡單移動平均線為 116.52 美元，200 日簡單移動平均線為 113.37 美元。</p>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same period last year, the business earned $0.35 EPS. The company's revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>TransMedics Group（納斯達克代碼：TMDX - 獲取免費報告）最後一次發佈季度財報是在 7 月 30 日。該公司報告本季度每股收益為 0.92 美元，超出分析師共識預期的 0.48 美元，超出幅度為 0.44 美元。TransMedics Group 的淨利潤率為 13.49%，股本回報率為 28.02%。該公司本季度的收入為 1.5737 億美元，而分析師預期為 1.4664 億美元。去年同期，該公司每股收益為 0.35 美元。與去年同期相比，該公司的收入增長了 37.7%。TransMedics Group 已設定其 2025 財年的每股收益指導。平均而言，股票分析師預計 TransMedics Group 本財年將發佈 1 美元的每股收益。</p>
</div><h2>Institutional Trading of TransMedics Group</h2>
<div class="lb-trans"><h2>TransMedics Group 的機構交易</h2>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻高增長股票，交易者熱愛，投資者應關注</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after buying an additional 2,209,996 shares during the period. Geode Capital Management LLC raised its holdings in TransMedics Group by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company's stock valued at $107,845,000 after buying an additional 11,241 shares during the period. Driehaus Capital Management LLC raised its holdings in TransMedics Group by 2.4% in the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company's stock valued at $52,395,000 after buying an additional 17,913 shares during the period. Marshall Wace LLP increased its stake in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company's stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after purchasing an additional 86,721 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近買入和賣出了該股票的股份。瑞銀資產管理美國有限公司的一個獨立業務部門在第一季度將其在 TransMedics Group 的持股增加了 244.7%。瑞銀資產管理美國有限公司的一個獨立業務部門現在擁有 3,113,082 股該公司的股票，價值 209,448,000 美元，在此期間又購買了 2,209,996 股。Geode Capital Management LLC 在第二季度將其在 TransMedics Group 的持股增加了 1.4%。Geode Capital Management LLC 現在擁有 804,650 股該公司的股票，價值 107,845,000 美元，在此期間又購買了 11,241 股。Driehaus Capital Management LLC 在第一季度將其在 TransMedics Group 的持股增加了 2.4%。Driehaus Capital Management LLC 現在擁有 778,754 股該公司的股票，價值 52,395,000 美元，在此期間又購買了 17,913 股。Marshall Wace LLP 在第二季度將其在 TransMedics Group 的持股增加了 258.7%。Marshall Wace LLP 現在擁有 546,787 股該公司的股票，價值 73,275,000 美元，在此期間又購買了 394,340 股。最後，高盛集團在第一季度將其在 TransMedics Group 的持股增加了 20.6%。高盛集團現在擁有 507,510 股該公司的股票，價值 34,145,000 美元，在此期間又購買了 86,721 股。99.67% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>TransMedics Group Company Profile</h2>
<div class="lb-trans"><h2>TransMedics Group 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.</p>
<div class="lb-trans"><p>TransMedics Group, Inc 是一家商業階段的醫療技術公司，致力於為美國及國際上的終末期器官衰竭患者轉變器官移植治療。該公司提供器官護理系統（OCS），這是一種便攜式器官灌注、優化和監測系統，利用其專有和定製技術在人體外複製接收器官的近生理條件。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 TransMedics Group</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>便士股票是否適合你的投資組合？</li>
<li>博通與 OpenAI 達成協議：為什麼這對 AVGO 股票是一個巨大的勝利</li>
<li>紐約證券交易所和納斯達克的區別，為什麼這對投資者很重要</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TMDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 TransMedics Group 嗎？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 TransMedics Group 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 TransMedics Group 並不在名單上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 TransMedics Group 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

TransMedics Group（納斯達克股票代碼：TMDX）的評級在 Wall Street Zen 被上調至買入